Breaking News
November 21, 2018 - Many people underestimate the impact of sprains, say foot scientists
November 21, 2018 - Lower levels of protein make squamous carcinoma cells more invasive
November 21, 2018 - Study highlights a new predictor of type 2 diabetes
November 21, 2018 - New low-cost injectable hydrogel could help wounds heal faster
November 21, 2018 - Merck Announces Winners of 2018 Life Science Awards
November 21, 2018 - Amount of weight regain after bariatric surgery helps predict health risks
November 21, 2018 - Heart failure patients with stronger hearts have more depressive symptoms, lower quality of life
November 21, 2018 - Women can be as resilient as men in undertaking arduous physical activity
November 21, 2018 - Receptor structure could be key to developing new osteoporosis drugs
November 21, 2018 - Researchers identify human white matter pathway associated with individual variability in human stereoacuity
November 21, 2018 - Vitamin D critical to early development of vertebrates, study suggests
November 21, 2018 - Myriad biological, societal factors that impact CKD severity for children of African descent
November 21, 2018 - Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
November 21, 2018 - Experts offer more clarity on managing common ankle fractures
November 21, 2018 - About 300 million bits of DNA are missing from basic reference genome, report scientists
November 21, 2018 - Study explores how the moving brain processes visual information
November 21, 2018 - Biomedical engineers stop cancer cells from moving and spreading
November 21, 2018 - Gut protein mutations protect against spikes in blood glucose levels
November 21, 2018 - First probabilistic atlas of thalamus nuclei to better understand the brain
November 21, 2018 - Peanut allergies could soon have a drug treatment
November 21, 2018 - Vanderbilt researchers isolate antibody that can neutralize West Nile virus
November 21, 2018 - KHN’s ‘What the Health?’ Health nerd books for the holidays
November 21, 2018 - MDMA could help gain trust but does not make one naive find researchers
November 21, 2018 - Study uncovers new mechanism controlling the master cancer regulator
November 21, 2018 - Online communication technologies could stave off depression among seniors, shows study
November 21, 2018 - FDA Approves Gamifant (emapalumab-lzsg) for Primary Hemophagocytic Lymphohistiocytosis
November 21, 2018 - Artificial intelligence predicts treatment effectiveness
November 21, 2018 - A bicyclist’s road to recovery after traumatic brain injury
November 21, 2018 - New research project to combat obesity, type 2 diabetes receives NIH funding
November 21, 2018 - Humans play key role in distribution and transmission of Bartonella bacteria
November 21, 2018 - First modeling system developed for testing age-specific human immune responses to vaccines
November 21, 2018 - FDA Alert: Gilenya (fingolimod): Drug Safety Communication
November 21, 2018 - Uric Acid Test: MedlinePlus Lab Test Information
November 21, 2018 - Researchers use genetics to predict response to antipsychotic medications
November 21, 2018 - Proposal to include the price of drugs in television ads is flawed, Stanford scholar writes
November 21, 2018 - Disrupting reproduction strategy of disease-causing parasites could help fight malaria
November 20, 2018 - ACAAI: Almost 2 Percent of Children Have Milk Allergy
November 20, 2018 - Congenital anomalies of kidney and urinary tract – Genetics Home Reference
November 20, 2018 - Can video games improve the health of older adults with schizophrenia?
November 20, 2018 - Can flicking a molecular switch restore the aging immune system’s competence?
November 20, 2018 - Restek launches new Oregon cannabis pesticide standards
November 20, 2018 - Health sector coalition urges Government to safeguard patients in future UK-EU relationship
November 20, 2018 - Study evaluates second-hand marijuana smoke exposure among children
November 20, 2018 - Scientists identify three genes responsible for recurrent molar pregnancies
November 20, 2018 - Researchers identify multisystem disorder caused by bi-allelic variants in CCDC47 gene
November 20, 2018 - Dining Out With Allergies Is Tough, But These Steps Can Help
November 20, 2018 - Breastfeeding protects infants from antibiotic-resistant bacteria
November 20, 2018 - AI matched, outperformed radiologists in screening X-rays for certain diseases | News Center
November 20, 2018 - Adolescents increasingly choose marijuana over cigarettes, alcohol
November 20, 2018 - World’s first medical imaging scanner produces diagnostic scan of the whole human body
November 20, 2018 - Cytocybernetics receives NIMH award to move into neuronal drug development
November 20, 2018 - Researchers discover new information on pathological mechanisms of Alzheimer’s disease
November 20, 2018 - ‘Unknown’ enzyme may be key to new treatment for inflammatory diseases
November 20, 2018 - Recreational drug may help people regain trust in others
November 20, 2018 - Researchers identify gene vital for post-stroke recovery
November 20, 2018 - Scientists identify novel target for neuron regeneration, functional recovery in spinal cord injury
November 20, 2018 - Potential new therapeutic approach developed for synovial sarcoma
November 20, 2018 - Skeletal imitation reveals how bones grow atom-by-atom
November 20, 2018 - Autism behaviors show unique brain network fingerprints in infants
November 20, 2018 - Location matters for inflammation clearance
November 20, 2018 - Towards finding a druggable cancer target
November 20, 2018 - Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
November 20, 2018 - Cooling ‘brains on fire’ to treat Parkinson’s
November 20, 2018 - Less pollution could increase the average lifespan of Copenhageners by an entire year in 2040
November 20, 2018 - Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network
November 20, 2018 - The plug and play time-resolved spectrometer from PicoQuant
November 20, 2018 - Breakthrough technology offers new hope to people with glaucoma, retinitis and macular degeneration
November 20, 2018 - New report highlights key focus areas to help cancer screening realize its full potential
November 20, 2018 - International experts to discuss strategies to maintain spatial orientation in old age
November 20, 2018 - Low-protein, high-carb diet may promote healthy brain ageing
November 20, 2018 - Scientists discover new inhibitor that decreases lung inflammation
November 20, 2018 - Participation project calls for relaxing research ban on germline interventions
November 20, 2018 - Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
November 20, 2018 - Arthritis by the Numbers: Book of Trusted Facts & Figures
November 20, 2018 - Drug homing method helps rethink Parkinson’s
November 20, 2018 - AHF commends the passage of global AIDS funding in the House, calls for swift approval
November 20, 2018 - The search for new psychiatric disorder treatments
November 20, 2018 - New research offers hope for simpler way to diagnose and treat cancer
November 20, 2018 - Study sheds light on the infection mechanism of influenza virus
November 20, 2018 - Storage failures of eggs and embryos gain a new perspective
Evoke Announces FDA Submission of New Drug Application for Gimoti

Evoke Announces FDA Submission of New Drug Application for Gimoti

image_pdfDownload PDFimage_print

Treatment for Gastroparesis

Evoke Announces FDA Submission of New Drug Application for Gimoti

SOLANA BEACH, Calif., June 04, 2018 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the submission of its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Gimoti™, the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

“Our NDA submission for Gimoti represents a significant step forward for Evoke and Gimoti, which has the potential to meaningfully improve the lives of patients who suffer from the devastating symptoms of gastroparesis,” commented Dave Gonyer, President and CEO. “Women represent an estimated 80% of all patients with the disease, which is characterized by debilitating episodes of nausea, vomiting, abdominal pain and bloating associated with delayed emptying of the stomach’s contents after meals. Vomiting and gastric emptying delays cause unpredictable absorption of food and oral medications which complicates glucose control and can lead to dehydration and malnutrition. Existing oral treatment options may be ineffective during an acute flare, which we believe creates the need for a nonoral treatment option. Gimoti delivers metoclopramide, a well-characterized motility and antiemetic drug, as a nasal spray. We believe that Gimoti can make an important difference in the lives of these patients and we look forward to FDA approval.”

Based on FDA timelines for review of the initial NDA submission, and Evoke’s NDA submission on Friday, June 1, 2018, the Company expects to receive notification from FDA the filing was accepted for substantive review in early August 2018.

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Metoclopramide is currently available only in oral and injectable formulations and is the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: the potential timing of FDA acceptance and approval, if any, of the NDA for Gimoti; the need for a nonoral treatment option for women suffering from gastroparesis; and the size of the patient population. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: the FDA may disagree that the existing safety database and efficacy data is sufficient to allow an NDA submission and approval, including risks associated with Cmax falling below the bioequivalence range in the comparative exposure PK trial and the proposed duration of use for Gimoti being shorter as compared to the maximum approved dosing duration for the referenced listed drug, Reglan Tablets, and the available safety database supporting such duration; the FDA may not agree with Evoke’s interpretation of the results of clinical trials of Gimoti; later developments with the FDA that may be inconsistent with the already completed pre-NDA meetings; the inherent risks of clinical development of Gimoti; Evoke is entirely dependent on the success of Gimoti, and Evoke cannot be certain that FDA will accept its NDA for Gimoti for substantive review or that Evoke will obtain regulatory approval for or successfully commercialize Gimoti; Evoke will require substantial additional funding to conduct any new safety trials required by the FDA, and may be unable to raise capital when needed, including to fund ongoing operations; and other risks detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Source: Evoke Pharma, Inc.

Posted: June 2018

Related Articles

Gimoti (metoclopramide) FDA Approval History

Tagged with:

About author

Related Articles